Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Goblet Study in Hamburg Germany repost
View:
Post by askretka on Aug 09, 2021 8:22pm

Goblet Study in Hamburg Germany repost

Roche, Oncolytics, AIO Partner to Study Virus-Based Treatment Combinations for GI Cancers --------------------------------------- "Under the terms of its latest collaboration with Roche, the drug giant will provide atezolizumab to Oncolytics for use in the pelareorep clinical development program. "Despite the great commercial success of checkpoint inhibitors, as many as four in five patients do not respond to these therapies in most GI malignancies, often due to an immunosuppressive tumor microenvironment," Dirk Arnold, director of the Asklepios Tumor Center in Hamburg and a principal investigator of the GOBLET study, said in a statement. "We believe that pelareorep treatment may substantially increase the proportion of patients who are eligible for, and respond to, checkpoint inhibitor therapy" ----------------------------------------------- Asklepios Klinik Barmbek, Germany:The Asklepios Group is the biggest private operator of hospitals in the entire European continent, but the Hamburg centre is regarded as the crown jewel. This is a general hospital, but it ranks among the best in matters of cutting edge innovation and medical technology. Companies release drugs and equipment in the Klinik before they are made available to the rest of the world, and the centre boasts of excellent nursing and rehabilitation facilities. The Asklepios Klinik boasts of the worlds best known medical laboratory, and is well known ------------------------------------------ This Hamburg clinic is rated #2 in the world just behind John Hopkins center according to an internet search. ----------------------------------------
Comment by fasttrack5 on Aug 09, 2021 8:59pm
https://stockhouse.com/news/press-releases/2021/08/06/oncolytics-biotech-xae-to-participate-in-virtual-fireside-chat-at-the-canaccord
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities